Apr 2026 $50 M No. 8 $50 to $250 million 1
Click Therapeutics, Inc.: Raise no. 8, Apr 2026 × Investors in this round 1 investor had bought by the notice of Oct 1, 2026: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David B. Klein · Executive Officer, Director Randall Stanicky · Executive Officer Alex Zisson · Director Anthony Costello · Director Bruce Robertson · Director · Mr. Robertson was elected a Director after the Date of First Sale and resigned prior to the date hereof. Cris De Luca · Director David Friedman · Director Douglas Langa · Director · Mr. Langa was elected a Director after the Date of First Sale. Jeffrey Berkowitz · Director Lezrene Cunningham · Director · Ms. Cunningham served as a Director on the date that the board approved the Offering and on the Date of First Sale. She Maria Forero · Director Muzammil Mansuri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David B. Klein, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 1, 2026. Read the notice at the SEC .
equity SEC Mar 2025 $49 M No. 7 $10 to $50 million 3
Click Therapeutics, Inc.: Raise no. 7, Mar 2025 × Investors in this round 3 investors had bought by the notice of Apr 1, 2025: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $49 M of $49 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David B. Klein · Executive Officer, Director Randall B. Stanicky · Executive Officer Alex B. Zisson · Director Anthony B. Costello · Director · Mr. Costello was elected a director upon the effectiveness of the Offering. Cris B. De Luca · Director David B. Friedman · Director Jeffrey B. Berkowitz · Director Lee B. Shapiro · Director Lezrene B. Cunningham · Director Maria B. Forero · Director Muzammil B. Mansuri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Total Amount Sold includes converted debt in the aggregate amount of $8,577,028.”On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David B. Klein, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 1, 2025. Read the notice at the SEC .
equity SEC May 2024 $3 M No. 6 $2 to $10 million 1
Click Therapeutics, Inc.: Raise no. 6, May 2024 × Investors in this round 1 investor had bought by the notice of Nov 21, 2024: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Klein · Executive Officer, Director Randall Stanicky · Executive Officer Alex Zisson · Director Cris De Luca · Director Jeffrey Berkowitz · Director Lee Shapiro · Director Lezrene Cunningham · Director Maria Forero · Director Muzammil Mansuri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David B. Klein, President and CEO. Source: SEC Form D, newest notice filed Nov 21, 2024. Read the notice at the SEC .
equity SEC Oct 2021 $52 M No. 5 $50 to $250 million 9
Click Therapeutics, Inc.: Raise no. 5, Oct 2021 × Investors in this round 9 investors had bought by the notice of Nov 5, 2021: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $52 M of $52 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Klein · Executive Officer, Director Randall Stanicky · Executive Officer Alex Zisson · Director · Mr. Zisson was elected as a director in connection with the offering. Cris De Luca · Director Jeff Berkowitz · Director Lee Shapiro · Director Muzammil Mansuri · Director Uri Geiger · Director · Mr. Geiger was elected as a director in connection with the offering. Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David B. Klein, President and CEO. Source: SEC Form D, newest notice filed Nov 5, 2021. Read the notice at the SEC .
equity SEC Jun 2018 $17 M No. 4 $10 to $50 million 50
Click Therapeutics, Inc.: Raise no. 4, Jun 2018 × Investors in this round 50 investors had bought by the notice of Jun 28, 2018: 50 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $17 M of $19 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Klein · Executive Officer, Director Ted Silver · Executive Officer John Sadowski · Director Nicholas Schork · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Jun 28, 2018. Read the notice at the SEC .
equity SEC Apr 2017 $4 M No. 3 $2 to $10 million 11
Click Therapeutics, Inc.: Raise no. 3, Apr 2017 × Investors in this round 11 investors had bought by the notice of Apr 20, 2017: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $5 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in New York People named in the notice David Klein · Executive Officer, Director Emile Westergaard · Director Nicholas Schork · Director Victor Gao · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Apr 20, 2017. Read the notice at the SEC .
debt, options SEC Jul 2015 $2 M No. 2 Under $2 million 18
Click Therapeutics, Inc.: Raise no. 2, Jul 2015 × Investors in this round 18 investors had bought by the notice of Aug 6, 2015: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $63,500
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in New York People named in the notice David Klein · Executive Officer, Director Emile Westergaard · Director Nicholas Schork · Director Victor Gao · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Emerson Equity LLC (CRD 130032) · broker-dealer Jonathan Sadowsky (CRD 2911276) · San Mateo, California Sold in DC, FL, MA, NY, PA, TN Remarks in the notice On fees: “The fee paid to the placement agent included a cash payment of $63,500 and warrants to purchase 63,500 shares of the company's Common Stock.”On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Aug 6, 2015. Read the notice at the SEC .
debt, options SEC Oct 2014 $1 M No. 1 Under $2 million 13
Click Therapeutics, Inc.: Raise no. 1, Oct 2014 × Investors in this round 13 investors had bought by the notice of Nov 4, 2014: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $3 M offered; $2 M still to sell
Smallest investment taken $25,000
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $109,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in New York People named in the notice David Klein · Executive Officer, Director Emile Westergaard · Director Nicholas Schork · Director Victor Gao · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Marta Zylka (CRD 5578030) · broker-dealer Merriman Capital, Inc. (CRD 18296) · New York, New York Sold in WA Zvi Ben-Zvi (CRD 2994766) · broker-dealer Merriman Capital, Inc. (CRD 18296) · New York, New York Sold in FL, MN, NJ, NY, TN, TX Remarks in the notice On fees: “The fee paid to the placement agent included a cash payment of $109,000.00 and a warrant to purchase 167,692 shares of the company's Common Stock.”On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Nov 4, 2014. Read the notice at the SEC .
debt, options SEC